Agence nationale de la recherche

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Cardiology, University, Hospital, IRB, Alteplase, AP, Type, University Hospitals Birmingham NHS Foundation Trust, Agence nationale de sécurité du médicament et des produits de santé, Partnership, Marketing, Assistance Publique–Hôpitaux de Paris, Stroke, Infarction, ISIN, RHU, Biologics license application, European Medicines Agency, Death, Quality of life, Pulmonary embolism, BLA, EVT, Sri Jayadeva Institute of Cardiovascular Sciences and Research, TNK, EMA, Agence nationale de la recherche, FDA, MRS, Disability, Tenecteplase, IRAS, Șaeș, Reperfusion, Standard of care, Safety, IPO, Modified Rankin Scale, Patient, Thrombectomy, Myocardial infarction, GREEN, Pharmaceutical industry, Medical imaging

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Key Points: 
  • ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.
  • We have fully met our patient enrollment goals in 2022 and are involving new countries and hospitals in 2023.
  • We look forward to continuing the clinical development of glenzocimab in the treatment of myocardial infarction in partnership with the University of Birmingham (UK).
  • The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe.

Research supported by Royal Commission for AlUla provides new insights into huge, ancient animal traps known as 'kites'

Retrieved on: 
Monday, October 24, 2022
Work, Socioeconomics, Development, Hunting, Animal, French National Centre for Scientific Research, Education, Bronze Age, Indira Gandhi National Centre for the Arts, Late, Research, RCU, Vision 2030, History, University, Arabian Archaeology and Epigraphy, Archaeological science, Agence nationale de la recherche, Veni, vidi, vici, Economic development, Scientific method, Press release, Agency, Nature, Late Neolithic, Domestication, Tourism, Epigraphy, Neolithic, Diffusion, Kingdom, Aerial archaeology, Chronology, University of Western Australia, CNRS, Toy, Archaeology, Harrat al-Sham, Al-'Ula, KSA

Dr Remy Crassard, a leading expert on desert kites, notes that they are some of the largest ancient structures of their era.

Key Points: 
  • Dr Remy Crassard, a leading expert on desert kites, notes that they are some of the largest ancient structures of their era.
  • Kites may have led to hunting well beyond subsistence levels, related to "an increase in symbolic behaviour related to food production and social organisation".
  • That hub, the Kingdoms Institute, is currently active as a research organization, with plans to open a physical presence at AlUla by 2030.
  • The RCU-sponsored research in and around AlUla is adding to the knowledge base that will inform the Kingdoms Institute.

Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021

Retrieved on: 
Saturday, November 13, 2021
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Health, Cold, GRID, SITC, Bladder cancer, Progression-free survival, PD-L1, Biomarker, Cancer, Lung cancer, IHC, Kidney, Therapy, Investor, Neoplasm, TILS, NanoString Technologies, Prostate cancer, Form 10-Q, Technology, CNRS, Society, ANR, Forward-looking statement, Thyroid cancer, Annual report, Partnership, Twitter, Idiopathic pulmonary fibrosis, Acquisition, Annual general meeting, Large-cell lung carcinoma, NSCLC, SEC, Breast cancer, Diagnosis, Hot, Society for Immunotherapy of Cancer, Immunotherapy, Agence nationale de la recherche, PFS, Patient, AstraZeneca, Pioneer, AMU, Pharmaceutical industry, Medical imaging

Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from three posters were presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, highlighting the companys immuno-oncology offerings for biopharmaceutical and academic researchers.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from three posters were presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, highlighting the companys immuno-oncology offerings for biopharmaceutical and academic researchers.
  • In the Hot subtype, for example, long-term progression-free survival (PFS) is observed for more than 40% of patients, regardless of PD-L1 status.
  • nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries, and used by Veracyte under license.
  • Immunoscore is the registered trademark of Inserm in the U.S. and selected countries, and is used by Veracyte under license.